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Risk of severe coronavirus disease 2019 (COVID-19) increases with age, is greater in 
males, and is associated with decreased numbers of blood lymphoid cells. Though the 
reasons for these robust associations are unclear, effects of age and sex on innate and 
adaptive lymphoid subsets, including on homeostatic innate lymphoid cells (ILCs) 
implicated in disease tolerance, may underlie the effects of age and sex on COVID-19 
morbidity and mortality. 
 
METHODS 
Flow cytometry was used to quantitate subsets of blood lymphoid cells from people 
infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comparing 
those hospitalized with severe COVID-19 (n=40) and those treated as outpatients for less 
severe disease (n=51). 86 healthy individuals served as controls. The relationship 
between abundance of specific blood lymphoid cell types, age, sex, hospitalization, 
duration of hospitalization, and elevation of blood markers for systemic inflammation, was 
determined using multiple regression. 
 
RESULTS 
After accounting for effects of age and sex, hospitalization for COVID-19 was associated 
with 1.78-fold fewer ILCs (95%CI: 2.34–1.36; p = 4.55 x 10-5) and 2.31-fold fewer CD16+ 
 . CC-BY-NC-ND 4.0 International licenseIt is made available under a 
 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)
The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.14.21249839doi: medRxiv preprint 
 
3 
natural killer (NK) cells (95%CI: 3.1–1.71; p = 1.04 x 10-7), when compared to uninfected 
controls. Among people infected with SARS-CoV-2, the odds ratio for hospitalization, 
adjusted for age, sex, and duration of symptoms, was 0.413 (95%CI: 0.197–0.724; p = 
0.00691) for every 2-fold increase in ILCs. In addition, higher ILC abundance was 
associated with less time spent in the hospital and lower levels of blood markers 
associated with COVID-19 severity: each two-fold increase in ILC abundance was 
associated with a 9.38 day decrease in duration of hospital stay (95% CI: 15.76–3.01; p 
= 0.0054), and decrease in blood C-reactive protein (CRP) by 46.29 mg/L (95% CI: 
71.34–21.24; p = 6.25 x 10-4), erythrocyte sedimentation rate (ESR) by 11.04 mm/h (95% 
CI: 21.94–0.13; p = 0.047), and the fibrin degradation product D-dimer by 1098.52 ng/mL 
(95% CI: 1932.84–264.19; p = 0.011). 
 
CONCLUSIONS 
Both ILCs and NK cells were depleted in the blood of people hospitalized for severe 
COVID-19, but, among lymphoid cell subsets, only ILC abundance was independently 
associated with the need for hospitalization, duration of hospital stay, and severity of 
inflammation. These results indicate that, by promoting disease tolerance, homeostatic 
ILCs protect against morbidity and mortality in SARS-CoV-2 infection, and suggest that 
reduction in the number of ILCs with age and in males accounts for the increased risk of 
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The risk of disease severity in people infected with SARS-CoV-2 increases with age and 
is greater for men than for women1–9. Similar trends exist in people infected with SARS-
CoV10–12 or MERS-CoV13, and have been observed in laboratory animals challenged with 
SARS-CoV or SARS-CoV-214,15. Yet, mechanisms underlying these effects of age and 
sex on COVID-19 morbidity and mortality remain poorly understood. The composition and 
function of the human immune system changes with age and exhibits sexual 
dimorphism16–19, with consequences for susceptibility to infection, autoimmune disease, 
and response to vaccination2,16,17,20–22. Better understanding of these effects might 
provide clues as to why the clinical outcome of SARS-CoV-2 infection is so variable. 
 Survival after infection with a pathogenic virus such as SARS-CoV-2 requires not 
only that the immune system control and eliminate the pathogen, but that disease 
tolerance mechanisms limit tissue damage caused by the pathogen or by host 
inflammatory responses23–25. Genetic and environmental factors identified in animal 
models influence disease tolerance mechanisms that promote host fitness without directly 
inhibiting replication of the pathogen23–28. Particular lymphoid cell types, including CD4+ 
T cells and innate lymphoid cells (ILCs), are implicated in promoting disease tolerance29–
34. SARS-CoV-2 viral load does not discriminate symptomatic from asymptomatic 
infection35–38, and this discrepancy between SARS-CoV-2 viral load and severity of 
COVID-19 is especially pronounced in children, who rarely manifest severe COVID-1939–
42, but may have viral loads as high as very sick adults43,44. These observations indicate 
that age-dependent, disease tolerance mechanisms influence the severity of COVID-19. 
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 COVID-19 severity correlates with lymphopenia45–50 and with reduction in specific 
blood lymphoid cell populations47,51–54. Nonetheless, assessment of lymphoid cell 
abundance, in the context of a disease for which age and sex are risk factors for severity, 
is complicated by differences in lymphocyte abundance with age and sex16,17. The goal 
of this observational study was to determine whether abundance of any blood lymphoid 
cell population correlates independently with clinical outcome of SARS-CoV-2 infection. 
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PERIPHERAL BLOOD MONONUCLEAR CELLS 
As part of a COVID-19 observational study, peripheral blood samples were collected from 
91 individuals with SARS-CoV-2 infection at the Massachusetts General Hospital and 
affiliated outpatient clinics. Request for access to coded patient samples was reviewed 
by the Massachusetts Consortium for Pathogen Readiness and approved by the 
University of Massachusetts Medical School IRB (protocol #H00020836). Some 
demographic, laboratory, and clinical outcome data were included with the coded 
samples. Samples from 86 blood donors, either collected prior to the SARS-CoV-2 
outbreak or from healthy individuals screened at a blood bank, were included as controls. 
 
FLOW CYTOMETRY 
Peripheral blood mononuclear cells (PBMCs) were stained with panels of fluorescent 
antibodies (Table S1) and detected on a BD Celesta flow cytometer using previously 
established gating strategies55. Cell subsets were identified using FlowJoTM software 
(Becton, Dickson and Company). Representative gating strategies are shown in Figure 
S1. 
 
STATISTICAL ANALYSIS AND DATA VISUALIZATION 
Data were prepared for analysis with the tidyverse56 package, and visualized using the 
ggplot257 and ggpubr58 packages, within the R computer software environment (version 
4.0.2)59. Multiple linear regression analysis tested for independent effects of age, sex, 
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and COVID-19 status on log2 transformed cell counts measured by flow cytometry, using 
the lm function in R. Pairwise group comparisons were performed on estimated marginal 
means generated from multiple linear regression using the emmeans package60, with 
multiple comparison correction using the Tukey adjustment. Association between log2 
transformed cell counts and hospitalization, in SARS-CoV-2-infected individuals, was 
determined with multiple logistic regression including age, sex, and duration of symptoms 
at time of blood collection, as additional independent variables using the glm function in 
R. Group differences in age and sex were determined with pairwise, two-sided, Wilcoxon 
rank-sum tests, or Fisher’s exact test, as indicated, with Bonferroni correction for multiple 
comparisons. 
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THREE GROUPS OF BLOOD DONORS 
The first group of blood donors included SARS-CoV-2-infected people hospitalized for 
severe COVID-19 (N = 40), among whom 33 (82.5%) were admitted to the ICU, 32 (80%) 
required intubation with mechanical ventilation, and 7 (17.5%) died (Table 1). This group 
had a mean age of 57.6 (range 24 to 83) and was 60% male. The second group consisted 
of people infected with SARS-CoV-2 but who did not require hospitalization for COVID-
19 (N=51). This group had a mean age of 36.8 years (range 23-77) and was 25.5% male 
(Table 1). Differences between the two SARS-CoV-2-infected groups, in terms of median 
age (p = 5.22 x 10-8) and sex ratio (p = 3.66 x 10-3) (Figure S2), were consistent with the 
established greater risk of severe COVID-19 in older individuals and in males1–6,8,61. The 
third group included 86 SARS-CoV-2-negative controls. The age of this group spanned 
the range of the two SARS-CoV-2-infected groups (mean age 50.9; range 23 to 79) and 
the percentage of males (56%) was similar to that of the hospitalized group (Table 1 and 
Figure S2). Available information concerning ethnicity and race of the blood donors was 
insufficient for statistical comparisons among the groups (Table S2).  
 
SARS-CoV-2 INFECTION AND LYMPHOID CELL ABUNDANCE 
The effect of COVID-19 severity on lymphocyte abundance was assessed by multiple 
linear regression, with age, sex, and group (hospitalized, outpatient, and uninfected), as 
independent variables. After accounting for effects of age and sex, total lymphocytes 
among PBMCs were decreased 1.33-fold (95%CI: 1.49–1.19; p = 1.22 x 10-6) in 
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comparison to uninfected controls (Table S3). The abundance of specific lymphoid cell 
populations, as a fraction of total lymphocytes, was then assessed. Holding age and sex 
constant, individuals hospitalized with COVID-19 had 1.78-fold fewer ILCs (95%CI: 2.34–
1.36; p = 4.55 x 10-5) and 2.31-fold fewer CD16+ natural killer (NK) cells (95%CI: 3.1–
1.71; p = 1.04 x 10-7), than did uninfected controls (Table S4 and Figure 1). After 
consideration of age and sex, neither CD4+ T cells nor CD8+ T cells were depleted (Table 
S4 and Figure 1). SARS-CoV-2-infected people who were treated as outpatients had no 
reduction in ILCs, but 1.44-fold fewer CD16+ NK cells (95%CI: 1.93–1.07; p = 1.68 x 10-
2), and 1.26-fold more CD4+ T cells (95%CI: 1.06–1.5; p = 0.01), than did uninfected 
controls (Table S4 and Figure 1). Estimated marginal means for uninfected, hospitalized, 
and outpatient groups, adjusted for age and sex, are shown in Figure 1. After accounting 
for the effect of group, the effects of age and sex on lymphoid cell abundance was 
consistent with previous reports16–19, with CD4+ T cells, CD8+ T cells, and ILCs decreasing 
with age, CD16+ NK cells increasing with age, and both CD4+ T cells and ILCs less 
abundant in males (Table S4 and Figure S3). 
 
ASSOCIATION OF LYMPHOID CELL ABUNDANCE WITH HOSPITALIZATION 
Association between lymphoid cell abundance and hospitalization in individuals infected 
with SARS-CoV-2 was determined with multiple logistic regression, including age, sex, 
and duration of symptoms at the time of blood draw, as additional independent variables. 
Abundance of ILCs, but not of CD16+ NK cells, CD4+ T cells, or CD8+ T cells was 
associated with odds of hospitalization: the odds ratio for hospitalization, adjusted for age, 
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sex, and symptom duration, was 0.413 (95%CI: 0.197–0.724; p = 0.00691), or a decrease 
of 58.7%, for each 2-fold increase in ILC abundance (Table 2).  
 
ASSOCIATION OF LYMPHOID CELL ABUNDANCE WITH DURATION OF  
HOSPITALIZATION AND MARKERS OF INFLAMMATION 
The relationship between lymphoid cell abundance and duration of hospital stay, or with 
peak blood values for markers of inflammation, was assessed with multiple linear 
regression, including age, sex, and cell abundance as independent variables. Holding 
age and sex constant, abundance of ILCs, but not of CD16+ NK cells, CD4+ T cells, or 
CD8+ T cells, was associated with length of time in the hospital, and with blood levels of 
markers associated with systemic inflammation (Table 3). Each two-fold increase in ILC 
abundance was associated with a 9.38 day decrease in duration of hospital stay (95% CI: 
15.76–3.01; p = 0.0054), 46.29 mg/L decrease in blood C-reactive protein (CRP) (95% 
CI: 71.34–21.24; p = 6.25 x 10-4), and 11.04 mm/h decrease in erythrocyte sedimentation 
rate (ESR) (95% CI: 21.94–0.13; p = 0.047). Abundance of both ILCs and CD4+ T cells 
was associated with blood levels of the fibrin degradation product D-dimer, with each two-
fold increase in cell abundance associated with a decrease in D-dimer by 1098.52 ng/mL 
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This study demonstrated that, after accounting for effects of age and sex, ILCs and CD16+ 
NK cells, but not CD4+ or CD8+ T cells, were decreased in individuals hospitalized with 
COVID-19 (Table S4 and Figure 1). Among people infected with SARS-CoV-2, higher 
abundance of ILCs, but not of NK cells or T cells, was associated with decreased odds of 
hospitalization, shorter duration of hospitalization, and lower blood level of factors 
associated with systemic inflammation (Table 3). Considering the known homeostatic 
function of ILCs55,62–65 and the host responses necessary to survive pathogenic 
infection23–25, these findings support the hypothesis that loss of disease tolerance 
mechanisms increase the risk of morbidity and mortality with SARS-CoV-2 infection66. 
 ILCs and NK cells are innate immune lymphoid cells that lack clonotypic antigen 
receptors but share many developmental and functional characteristics with T 
cells30,62,63,67,68. Like CD8+ T cells, NK cells kill virus-infected cells using perforin and 
granzyme30,67. FcγRIII (CD16)-positive NK cells link innate and acquired immunity by 
binding virus-specific immunoglobulins that target virus-infected cells for antibody-
dependent cellular cytotoxicity69. The lack of association in this study between the 
abundance of these CD16+ NK cells and odds of hospitalization, duration of 
hospitalization, or blood markers of inflammation, is consistent with the paradoxical 
finding that individuals with severe COVID-19 have more robust SARS-CoV-2-
neutralizing antibody responses70,71. Findings such as these indicate that stronger 
adaptive antiviral immune responses do not necessarily result in decreased morbidity and 
improved survival. 
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 ILCs represent innate counterparts of CD4+ T cells30,67 that promote tissue 
homeostasis and repair55,62–65, maintaining the integrity of epithelial barriers in the lung 
and intestine29–32. ILCs with a similar marker profile to those detected in the blood are 
found in human lung and bronchoalveolar fluid29, and experiments with animal models 
demonstrate that these ILCs promote airway epithelial integrity and restore tissue 
homeostasis in the lung after challenge with influenza virus29. Reduction in blood ILCs in 
people with HIV-1 infection correlates with decrease in colon lamina propria ILCs55, 
suggesting that the reduction in blood ILCs reported here with SARS-CoV-2 reflects 
tissue abundance of these cells. Decreased abundance of ILCs with increasing age and 
male sex (Table S4 and Figure S3) may therefore explain why morbidity and mortality 
associated with SARS-CoV-2 infection is worse in males and more severe with older 
age1–6,8,61. This conclusion is also supported by the association reported here between 
ILC abundance, odds of hospitalization, length of stay in the hospital, and levels of the 
markers of COVID-19 severity, CRP, ESR, and D-dimer9,72–74 (Table 3).  
 In conclusion, these results support the idea that the clinical outcome of SARS-
CoV-2 infection is at least in part dependent upon disease tolerance mechanisms, 
reflected in peripheral blood counts of homeostatic ILCs, and, additionally offer potential 
explanation for the effects of age and sex on risk of morbidity and mortality. The findings 
of this observational study warrant establishment of prospective cohort studies to 
determine whether abundance of ILCs, or of other lymphoid cell subsets associated with 
disease tolerance29–34, predict clinical outcome for infection with SARS-CoV-2 or other 
lethal pathogens.   
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Table 1: Demographic and Clinical Characteristics of Blood Donor Groups 





Mean age (range) - years  50.9 (23-79) 57.6 (24-83) 36.8 (23-77) 
Sex – number (%)    
Male 48 (55.8) 24 (60) 13 (25.5) 
Female 38 (44.2) 16 (40)  38 (74.5) 
Mean symptom duration at sample 
collection (range) – days 
 21.8 (5-66) 26.9 (1-61) 
ICU admission – number (%)  33 (82.5)  
Intubation with mechanical 
ventilation – number (%) 
 32 (80)  
Deaths – number (%)  7 (17.5)  
Max lab value – mean (range)    
CRP – mg/L  228.6 (6.5-539.5)  
ESR – mm/h  89.0 (15-146)  
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Table 2: Odds of Hospitalization* 
Cell count† Odds Ratio‡ 95% Confidence Interval P-Value 
CD4+ T 0.501 0.184–1.07 0.106 
ILC 0.413 0.197–0.724 0.007 
CD8+ T 1.22 0.635–2.64 0.579 
CD16+ NK 0.814 0.53–1.21 0.309 
*Adjusted for age, sex, and symptom duration at time of sample collection 
† per 106 lymphocytes 
‡ per 2-fold increase in cell population abundance 
Table 3:  Association of cell type abundance with time in hospital and laboratory values† 
Cell count‡ Days hospitalized CRP§ ESR§ D-dimer§ 
CD4+ T 
-10.843 -3.335 -2.674 -1868.847* 
[-22.511, 0.825] [-56.162, 49.492] [-23.840, 18.492] [-3375.630, -362.063] 
ILC 
-9.381** -46.288*** -11.035* -1098.515* 
[-15.755, -3.008] [-71.337, -21.238] [-21.936, -0.134] [-1932.842, -264.188] 
CD8+ T 
3.366 32.247 15.317 486.192 
[-8.992, 15.724] [-16.509, 81.003] [-4.127, 34.761] [-1049.836, 2022.221] 
CD16+ NK 
-4.775 -14.619 -5.159 -404.873 
[-11.251, 1.701] [-44.011, 14.774] [-16.809, 6.491] [-1316.261, 506.516] 
* p < 0.05, ** p < 0.01, *** p < 0.001 
† coefficients are for each two-fold increase in cell population abundance, adjusted for age and sex [±95%CI] 
‡ per 106 lymphoid cells 
§ Maximum lab value recorded during course of hospitalization 
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Figure 1: Difference in lymphoid cell abundance by group, shown as estimated marginal 
means, ±95CI, generated from the multiple linear regressions in Table S4, and averaged 
across age and sex. Cell counts are per million lymphocytes. P-values represent pairwise 
comparisons on the estimated marginal means, adjusted for multiple comparisons with 
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Table S1: Antibodies Used in Flow Cytometry 
Targeting antigen Company Catalog Number/Clone/Fluorophore 
Anti-Human BDCA1 Biolegend Cat# 354208 Clone: 201A (FITC) (1:200 dilution) 
Anti-Human CD117 Biolegend Cat# 313206 Clone: 104D2 (APC) (1:200 dilution) 
Anti-Human CD11c Biolegend Cat# 301604 Clone: 3.9 (FITC) (1:200 dilution) 
Anti-Human CD123 Biolegend Cat# 306014 Clone: 6H6 (FITC) (1:200 dilution) 
Anti-Human CD127 Biolegend Cat# 351320 Clone: A019D5 (PE/Cyanine7) (1:200 dilution) 
Anti-Human CD14 Biolegend Cat# 325604 Clone: HCD14 (FITC) (1:200 dilution) 
Anti-Human CD16         Biolegend   Cat# 980104 Clone: 3G8 (APC) (1:400 diltuion) 
Anti-Human CD19 Biolegend Cat# 302206 Clone: HIB19 (FITC) (1:200 dilution) 
Anti-Human CD1a Biolegend Cat# 300104 Clone: HI149 (FITC) (1:200 dilution) 
Anti-Human CD20         Biolegend   Cat# 302304 Clone: 2H7a (FITC) (1:200 dilution) 
Anti-Human CD22         Biolegend   Cat# 363508 Clone: S-HCL-1 (FITC) (1:200 dilution) 
Anti-Human CD3 Biolegend Cat# 317306 Clone: OKT3 (FITC) (1:200 dilution) 
Anti-Human CD34 Biolegend Cat# 343504 Clone: 581 (FITC) (1:200 dilution) 
Anti-Human CD4          Biolegend  Cat# 317428 Clone: OKT4 (PerCP/Cyanine5.5) (1:200 dilution) 
Anti-Human CD4          Biolegend  Cat# 317408 Clone: OKT4 (FITC) (1:200 dilution) 
Anti-Human CD45 BD Cat# 506178 Clone: 2D1 (APC/H7) (1:200 diltuion) 
Anti-Human CD56 Biolegend Cat# 318306 Clone: HCD56 (PE) (1:200 dilution) 
Anti-Human CD8 Biolegend Cat# 300924 Clone: HIT8a (PerCP/Cyanine 5.5) (1:200 dilution) 
Anti-Human CRTH2 Biolegend Cat# 350116 Clone: BM16 (PerCP/Cyanine5.5) (1:200 dilution) 
Anti-Human FcεR1α Biolegend Cat# 334608 Clone: AER-37 (FITC) (1:200 dilution) 
Anti-Human TBX21 ebioscience  Cat# 25-5825-82 Clone: ebio4B10 (PE/Cyanine7) (1:200 dilution) 
Anti-Human TCRα/β Biolegend Cat# 306706 Clone: IP26 (FITC) (1:200 dilution) 
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Table S2: Race and Ethnicity of Cohorts  





Race or ethnic group – number (%)    
White 25 (29.1) 17 (42.5) 46 (90.2) 
Black or African American 0 (0) 6 (15) 2 (3.9) 
Asian 1 (1.2) 1 (2.5) 1 (2) 
Unknown or not reported 60 (69.8) 16 (40) 2 (3.9) 
Hispanic or latinx 1 (1.2) 11 (27.5) 3 (5.9) 


































Table S3: Change in Cell Abundance Due to 
Age, Sex, and COVID-19 Severity 
Fold difference (log2) [±95%CI]  
 Lymphocytes† 
Age -0.008*** [-0.012, -0.004] 
Male -0.267*** [-0.400, -0.135] 
Hospitalized -0.411*** [-0.572, -0.250] 
Outpatient 0.129 [-0.030, 0.289] 
R2 0.416 
* p < 0.05, ** p < 0.01, *** p < 0.001 
† per 106 PBMCs ‘  
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Table S4: Change in Cell Abundance Due to Age, Sex, and COVID-19 Severity 
Fold difference (log2) [±95%CI]     
 CD4+ T† ILC† CD8+ T† CD16+ NK† 
Age -0.012*** -0.043*** -0.009* 0.021*** 
 [-0.018, -0.005] [-0.053, -0.033] [-0.016, -0.002] [0.010, 0.032] 
Male -0.409*** -0.334* -0.177 0.184 
 [-0.618, -0.201] [-0.659, -0.010] [-0.406, 0.051] [-0.169, 0.538] 
Hospitalized 0.168 -0.835*** 0.227 -1.205*** 
 [-0.084, 0.421] [-1.228, -0.441] [-0.050, 0.503] [-1.633, -0.778] 
Outpatient 0.332* -0.088 -0.023 -0.522* 
 [0.082, 0.581] [-0.478, 0.302] [-0.298, 0.253] [-0.948, -0.095] 
R2 0.275 0.478 0.070 0.232 
* p < 0.05, ** p < 0.01, *** p < 0.001 
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Figure S1: Representative gating strategy. All cell subsets were first gated on lymphoid 
cells, singlets, live/dead, and CD45+ (A). ILCs were identified as Lin-CD56-CD16-CD127+ 
using 14 lineage markers (B). CD16+ NK cells were identified as Lin-TBX21+CD16+ (C). 
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Figure S2: Age and fraction male of groups included in the study with P-values from 
pairwise two-sided Wilcoxon rank-sum and Fisher’s exact test, respectively, with 
Bonferroni correction for multiple comparisons. Box plots represent the distribution of the 
data with the center line drawn through the median with the upper and lower bounds of 
the box at the 75th and 25th percentiles respectively. The upper and lower whiskers 
extend to the largest or smallest values within 1.5 x the interquartile range (IQR). The 
notch spans roughly the 95% confidence interval around the median as given by 1.58 x 
IQR/n^0.5. 
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Figure S3: Visualization of change in log2 abundance of lymphoid cell populations with 
age as determined with the regression analysis in Table S4. Regression lines, R2, and P-
values are all from the associated multiple regression analyses and shading represents 
the 95%CI (A). Sex differences in lymphoid cell abundance shown as estimated marginal 
means ±95CI generated from the multiple linear regressions in Table S4 and averaged 
across age and group. 
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